Pharmaceutical company Elan says it hopes to bring its Prialt pain treatment on to the market no later than the first quarter of 2005, following what it describes as positive results from recent trials.
Elan will now file an amendment to its New Drug Application with the US Food and Drug Administration in the second quarter of this year. Elan submitted an application to market Prialt in the EU in May last year.
The recent trials were conducted in response to a request from the FDA for additional information. Elan said the treatment appeared to be safe and effective.
Elan shares closed up 44 cent to €5.84 on the ISEQ this evening.
